The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery

Thomas F. Slaughter, Fariba Faghih, Charles S. Greenberg, John B. Leslie, Robert N. Sladen

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Despite the efficacy of antifibrinolytic drugs in reducing bleeding after cardiac surgery, concerns remain regarding their potential to promote thrombosis. We examined the effect of the antifibrinolytic drug, ε- aminocaproic acid (EACA) on fibrinolysis and thrombin generation during cardiac surgery. Forty-one adults undergoing primary coronary artery bypass graft surgery requiring cardiopulmonary bypass (CPB) were prospectively randomized in a double-blind trial to receive either saline or EACA. A loading dose of 150 mg/kg EACA was given before anesthetic induction, followed by a 15 mg·kg-1η-1 infusion, which continued until 3 h after CPB. Plasma samples for the measurement of D-dimer, thrombin-antithrombin III, and soluble fibrin were obtained before surgery, 1 h on CPB, and 3 and 20 h after CPB. In the EACA group, fibrinolytic activity, as measured by D- dimer, was significantly decreased 3 h after CPB, (0.51 ± 0.15 mg/L vs 1.13 ± 0.14 mg/L, P < 0.005). Decreased fibrinolytic activity was accompanied by decreased bleeding in the EACA group (660 ± 127 mL vs 931 ± 113 mL, P < 0.05). No differences in the generation of thrombin or soluble fibrin were apparent between the two groups. Suppression of fibrinolytic activity in the absence of concomitant reductions in thrombin generation suggests that EACA could potentiate a hypercoagulable prethrombotic state in the perioperative setting. Implications: In a randomized, prospective trial of primary cardiac surgery, we demonstrated that the synthetic antifibrinolytic drug ε- aminocaproic acid suppresses fibrinolysis with no effects on thrombin generation. These results suggest the potential for synthetic antifibrinolytic drugs to induce a hypercoagulable prethrombotic state in the perioperative setting.

Original languageEnglish (US)
Pages (from-to)1221-1226
Number of pages6
JournalAnesthesia and Analgesia
Volume85
Issue number6
DOIs
StatePublished - 1997

Fingerprint

Aminocaproic Acid
Antifibrinolytic Agents
Fibrinolysis
Thrombin
Thoracic Surgery
Cardiopulmonary Bypass
Pharmaceutical Preparations
Fibrin
Hemorrhage
Cohort Effect
Antithrombin III
Coronary Artery Bypass
Anesthetics
Thrombosis
Transplants

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. / Slaughter, Thomas F.; Faghih, Fariba; Greenberg, Charles S.; Leslie, John B.; Sladen, Robert N.

In: Anesthesia and Analgesia, Vol. 85, No. 6, 1997, p. 1221-1226.

Research output: Contribution to journalArticle

Slaughter, Thomas F. ; Faghih, Fariba ; Greenberg, Charles S. ; Leslie, John B. ; Sladen, Robert N. / The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. In: Anesthesia and Analgesia. 1997 ; Vol. 85, No. 6. pp. 1221-1226.
@article{188df7f891cc4467b73aa8251b5d300b,
title = "The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery",
abstract = "Despite the efficacy of antifibrinolytic drugs in reducing bleeding after cardiac surgery, concerns remain regarding their potential to promote thrombosis. We examined the effect of the antifibrinolytic drug, ε- aminocaproic acid (EACA) on fibrinolysis and thrombin generation during cardiac surgery. Forty-one adults undergoing primary coronary artery bypass graft surgery requiring cardiopulmonary bypass (CPB) were prospectively randomized in a double-blind trial to receive either saline or EACA. A loading dose of 150 mg/kg EACA was given before anesthetic induction, followed by a 15 mg·kg-1η-1 infusion, which continued until 3 h after CPB. Plasma samples for the measurement of D-dimer, thrombin-antithrombin III, and soluble fibrin were obtained before surgery, 1 h on CPB, and 3 and 20 h after CPB. In the EACA group, fibrinolytic activity, as measured by D- dimer, was significantly decreased 3 h after CPB, (0.51 ± 0.15 mg/L vs 1.13 ± 0.14 mg/L, P < 0.005). Decreased fibrinolytic activity was accompanied by decreased bleeding in the EACA group (660 ± 127 mL vs 931 ± 113 mL, P < 0.05). No differences in the generation of thrombin or soluble fibrin were apparent between the two groups. Suppression of fibrinolytic activity in the absence of concomitant reductions in thrombin generation suggests that EACA could potentiate a hypercoagulable prethrombotic state in the perioperative setting. Implications: In a randomized, prospective trial of primary cardiac surgery, we demonstrated that the synthetic antifibrinolytic drug ε- aminocaproic acid suppresses fibrinolysis with no effects on thrombin generation. These results suggest the potential for synthetic antifibrinolytic drugs to induce a hypercoagulable prethrombotic state in the perioperative setting.",
author = "Slaughter, {Thomas F.} and Fariba Faghih and Greenberg, {Charles S.} and Leslie, {John B.} and Sladen, {Robert N.}",
year = "1997",
doi = "10.1097/00000539-199712000-00008",
language = "English (US)",
volume = "85",
pages = "1221--1226",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery

AU - Slaughter, Thomas F.

AU - Faghih, Fariba

AU - Greenberg, Charles S.

AU - Leslie, John B.

AU - Sladen, Robert N.

PY - 1997

Y1 - 1997

N2 - Despite the efficacy of antifibrinolytic drugs in reducing bleeding after cardiac surgery, concerns remain regarding their potential to promote thrombosis. We examined the effect of the antifibrinolytic drug, ε- aminocaproic acid (EACA) on fibrinolysis and thrombin generation during cardiac surgery. Forty-one adults undergoing primary coronary artery bypass graft surgery requiring cardiopulmonary bypass (CPB) were prospectively randomized in a double-blind trial to receive either saline or EACA. A loading dose of 150 mg/kg EACA was given before anesthetic induction, followed by a 15 mg·kg-1η-1 infusion, which continued until 3 h after CPB. Plasma samples for the measurement of D-dimer, thrombin-antithrombin III, and soluble fibrin were obtained before surgery, 1 h on CPB, and 3 and 20 h after CPB. In the EACA group, fibrinolytic activity, as measured by D- dimer, was significantly decreased 3 h after CPB, (0.51 ± 0.15 mg/L vs 1.13 ± 0.14 mg/L, P < 0.005). Decreased fibrinolytic activity was accompanied by decreased bleeding in the EACA group (660 ± 127 mL vs 931 ± 113 mL, P < 0.05). No differences in the generation of thrombin or soluble fibrin were apparent between the two groups. Suppression of fibrinolytic activity in the absence of concomitant reductions in thrombin generation suggests that EACA could potentiate a hypercoagulable prethrombotic state in the perioperative setting. Implications: In a randomized, prospective trial of primary cardiac surgery, we demonstrated that the synthetic antifibrinolytic drug ε- aminocaproic acid suppresses fibrinolysis with no effects on thrombin generation. These results suggest the potential for synthetic antifibrinolytic drugs to induce a hypercoagulable prethrombotic state in the perioperative setting.

AB - Despite the efficacy of antifibrinolytic drugs in reducing bleeding after cardiac surgery, concerns remain regarding their potential to promote thrombosis. We examined the effect of the antifibrinolytic drug, ε- aminocaproic acid (EACA) on fibrinolysis and thrombin generation during cardiac surgery. Forty-one adults undergoing primary coronary artery bypass graft surgery requiring cardiopulmonary bypass (CPB) were prospectively randomized in a double-blind trial to receive either saline or EACA. A loading dose of 150 mg/kg EACA was given before anesthetic induction, followed by a 15 mg·kg-1η-1 infusion, which continued until 3 h after CPB. Plasma samples for the measurement of D-dimer, thrombin-antithrombin III, and soluble fibrin were obtained before surgery, 1 h on CPB, and 3 and 20 h after CPB. In the EACA group, fibrinolytic activity, as measured by D- dimer, was significantly decreased 3 h after CPB, (0.51 ± 0.15 mg/L vs 1.13 ± 0.14 mg/L, P < 0.005). Decreased fibrinolytic activity was accompanied by decreased bleeding in the EACA group (660 ± 127 mL vs 931 ± 113 mL, P < 0.05). No differences in the generation of thrombin or soluble fibrin were apparent between the two groups. Suppression of fibrinolytic activity in the absence of concomitant reductions in thrombin generation suggests that EACA could potentiate a hypercoagulable prethrombotic state in the perioperative setting. Implications: In a randomized, prospective trial of primary cardiac surgery, we demonstrated that the synthetic antifibrinolytic drug ε- aminocaproic acid suppresses fibrinolysis with no effects on thrombin generation. These results suggest the potential for synthetic antifibrinolytic drugs to induce a hypercoagulable prethrombotic state in the perioperative setting.

UR - http://www.scopus.com/inward/record.url?scp=0031284642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031284642&partnerID=8YFLogxK

U2 - 10.1097/00000539-199712000-00008

DO - 10.1097/00000539-199712000-00008

M3 - Article

VL - 85

SP - 1221

EP - 1226

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -